4/25
10:03 am
cycc
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers [Seeking Alpha]
Medium
Report
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers [Seeking Alpha]
4/25
08:33 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future [Yahoo! Finance]
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future [Yahoo! Finance]
4/24
02:11 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
4/16
02:07 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
4/1
09:15 am
cycc
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Medium
Report
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
3/26
02:31 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/20
10:17 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/19
04:10 pm
cycc
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/19
04:05 pm
cycc
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/18
11:06 pm
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/13
04:05 pm
cycc
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
3/7
11:05 pm
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/7
09:29 am
cycc
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
Neutral
Report
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
3/7
09:15 am
cycc
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Medium
Report
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
3/6
09:20 am
cycc
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit [Yahoo! Finance]
Medium
Report
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit [Yahoo! Finance]
3/6
09:15 am
cycc
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
Medium
Report
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
2/20
09:15 am
cycc
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
Low
Report
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
2/12
01:08 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/4
01:12 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
1/30
09:23 am
cycc
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer [Yahoo! Finance]
1/30
09:15 am
cycc
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
Medium
Report
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
1/27
04:44 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.